IMMUNOVANT INC. - COMMON STOCK

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

21 4 2025 06:00:00 提供 Nasdaq GlobeNewswire

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

19 3 2025 06:45:00 提供 Nasdaq GlobeNewswire

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

18 3 2025 15:32:00 提供 Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

06 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Immunovant Announces $450 Million Private Placement

13 1 2025 07:00:01 提供 Nasdaq GlobeNewswire

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

07 11 2024 05:30:00 提供 Nasdaq GlobeNewswire

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

29 10 2024 05:30:00 提供 Nasdaq GlobeNewswire

Immunovant Provides Update on Graves’ Disease Development Program

09 9 2024 02:55:00 提供 Nasdaq GlobeNewswire

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

05 9 2024 05:30:00 提供 Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

06 8 2024 15:05:01 提供 Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

29 5 2024 15:01:00 提供 Nasdaq GlobeNewswire

Immunovant Awarded U.S. Patent for IMVT-1402

12 3 2024 06:30:04 提供 Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

12 2 2024 06:00:00 提供 Nasdaq GlobeNewswire

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

20 12 2023 15:30:00 提供 Nasdaq GlobeNewswire

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

28 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

Immunovant to Present at Upcoming Investor Conferences

13 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

09 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

02 10 2023 15:52:02 提供 Nasdaq GlobeNewswire

Immunovant Announces Pricing of $450 Million Common Stock Financing

27 9 2023 22:41:51 提供 Nasdaq GlobeNewswire